**(E)-N-(3-Chlorophenyl)-6-(2-(4-(trifluoromethoxy)benzylidene)hydrazinyl)pyrazine-2-carboxamide, OSM-S-XXX**

****

Representative Example: http://malaria.ourexperiment.org/uri/6da

Prepared according to General Procedure **X** from: \_\_\_ to give the title compound as a pale yellow solid (312 mg, 94%); **m.p.** 250.2–250.5 ˚C; **IR** νmax (film) /cm-1 3322, 3257, 1671, 1577, 1432, 1310, 1144; **1H NMR** (400 MHz, DMSO-d*6*) δ: 11.60 (1H, s), 10.46 (1H, s), 8.91 (1H, s), 8.60 (1H, s), 8.18 (1H, s), 8.03 (1H, t, *J* 2.0), 7.92 (2H, dapp, *J* 8.8), 7.71 (1H, dd, *J* 8.2, 2.1), 7.42 (2H, dapp, *J* 8.7), 7.42 (1H, t, *J* 8.1), 7.21 (1H, dd, *J* 8.0, 2.1); **13C NMR** (125 MHz, DMSO-d*6*) δ: 162.59, 151.14, 148.69, 142.37, 140.57, 139.63, 134.08, 133.94, 133.63, 133.13, 130.55, 128.37, 123.85, 121.30, 119.46, 118.44; **m/z** (ESI+) 436 [M+H]+; **HRMS** (APCI+) found 436.07823 [M+H]+, C19H14ClF3N5O2 requires 436.07826.

*O=C(NC1=CC=CC(Cl)=C1)C2=CN=CC(N/N=C/C3=CC=C(OC(F)(F)F)C=C3)=N2*

*InChI=1S/C19H13ClF3N5O2/c20-13-2-1-3-14(8-13)26-18(29)16-10-24-11-17(27-16)28-25-9-12-4-6-15(7-5-12)30-19(21,22)23/h1-11H,(H,26,29)(H,27,28)/b25-9+*